Engineered heart tissues and induced pluripotent stem cells: Macro and microstructures for disease modeling, drug screening, and translational studies.
Engineered heart tissue has emerged as a personalized platform for drug screening. With the advent of induced pluripotent stem cell (iPSC) technology, patient specific stem cells can be developed and expanded into an indefinite source of cells. Subsequent developments in cardiovascular biology have led to efficient differentiation of cardiomyocytes, the force producing cells of the heart. iPSC derived cardiomyocytes (iPSC CMs) have provided potentially limitless quantities of well characterized, healthy, and disease specific CMs, which in turn has enabled and driven the generation and scale up of human physiological and disease relevant engineered heart tissues. The combined technologies of engineered heart tissue and iPSC CMs are being used to study diseases and to test drugs, and in the process, have advanced the field of cardiovascular tissue engineering into the field of precision medicine. In this review, we will discuss current developments in engineered heart tissue, including iPSC CMs as a novel cell source. We examine new research directions that have improved the function of engineered heart tissue by using mechanical or electrical conditioning or the incorporation of non cardiomyocyte stromal cells. Finally, we discuss how engineered heart tissue can evolve into a powerful tool for therapeutic drug testing.
Advanced drug delivery reviews